All In MedTech

Device Trial Radar · NCT01891760

Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

A Prospective, Multi-center, Longitudinal, Cohort Study of Dermagraft in Subjects With Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial

Last checked: Nov 21, 2026Latest source record: Aug 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

May 2010

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Shire Regenerative Medicine, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 3, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* Observe the long-term (1-year) outcomes of Dermagraft, compared with conventional treatment of four-layer compression bandaging therapy alone, in subjects who completed the ABH-Dermagraft-001-08 study. * Study Hypothesis: N/A (Long-term follow-up study)

Conditions

  • Venous Leg Ulcer

Interventions

  • DermagraftDevice

    Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).

  • ProforeDevice

    Four-layer compression bandaging therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of study ulcer recurrenceTime frame: 1 year

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Carl T. Hayden VA Medical Center

    Phoenix, Arizona

27 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.